Relt Elisabeth, Roll Wolfgang, Claesener Michael, Bögemann Martin, Weckesser Matthias, Rahbar Kambiz
Department of Nuclear Medicine, University Hospital Münster, 48149 Münster, Germany.
West German Cancer Center, 48149 Münster, Germany.
Cancers (Basel). 2022 Oct 20;14(20):5141. doi: 10.3390/cancers14205141.
PET imaging using PSMA ligands is increasingly used for staging in prostate cancer patients in different clinical indications. Unlike [Ga]Ga-labeled PSMA ligands, fluorinated compounds can be produced in large amounts; thus, they can be used for a higher number of patients. One concern is that in patients studied a long time after synthesis (TaS) or time after injection (TaI), the specific activity may decline; thus, the signal may be lower in these patients. In this study, we investigated a potential effect of TaS and TaI on image quality. In total, 134 consecutive patients were included in this retrospective analysis on the effect of TaS and TaI on uptake in prostate cancer lesions. All the patients underwent [F]F-PSMA-1007 PET-CT from 99 min up to 549 min after tracer quality control. TaS and TaI were compared to the quantitative tumoral uptake parameters SUVmax and SUVpeak. In a second exploratory part of the analysis, TaS and TaI were correlated to a physiological tracer uptake in different organs. TaS and TaI did not affect the SUVmax and SUVpeak in tumor lesions in [F]F-PSMA-1007 PET. The physiological uptake in salivary glands, lacrimal glands and the ganglia, spleen and urine was not significantly correlated to TaS or TaI; in contrast to the mean liver uptake, showing a weak, but significant correlation to TaS. The [F]F-PSMA-1007 uptake in prostate cancer lesions is not significantly dependent on the TaS and TaI. These results are extremely reassuring when performing [F]F-PSMA-1007 PET a considerable time after synthesis.
使用前列腺特异性膜抗原（PSMA）配体的正电子发射断层扫描（PET）成像越来越多地用于不同临床适应症的前列腺癌患者的分期。与[镓]镓标记的PSMA配体不同，氟化化合物可以大量生产；因此，它们可用于更多患者。一个担忧是，在合成后很长时间（TaS）或注射后时间（TaI）进行研究的患者中，比活可能会下降；因此，这些患者的信号可能较低。在本研究中，我们调查了TaS和TaI对图像质量的潜在影响。总共134名连续患者被纳入这项关于TaS和TaI对前列腺癌病灶摄取影响的回顾性分析。所有患者在示踪剂质量控制后99分钟至549分钟内接受了[氟]F-PSMA-1007 PET-CT检查。将TaS和TaI与定量肿瘤摄取参数SUVmax和SUVpeak进行比较。在分析的第二个探索性部分中，TaS和TaI与不同器官的生理性示踪剂摄取相关。TaS和TaI在[氟]F-PSMA-1007 PET中不影响肿瘤病灶的SUVmax和SUVpeak。唾液腺、泪腺和神经节、脾脏和尿液中的生理性摄取与TaS或TaI无显著相关性；与肝脏平均摄取相反，肝脏平均摄取与TaS呈弱但显著的相关性。前列腺癌病灶中的[氟]F-PSMA-1007摄取并不显著依赖于TaS和TaI。当在合成后相当长的时间进行[氟]F-PSMA-1007 PET检查时，这些结果非常令人放心。
